Andrés J.M. Ferreri

Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

Lauren E. Abrey, Tracy T. Batchelor, Andrés J.M. Ferreri et al. · Journal of Clinical Oncology · 2005 · 882 citations

Pcnsl Survivors, Primary Cns Lymphoma, Pathology +17

Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

Andrés J.M. Ferreri, Jean‐Yves Blay, Michele Reni et al. · Journal of Clinical Oncology · 2003 · 824 citations

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program

Shimin Hu, Zijun Y. Xu‐Monette, Alexandar Tzankov et al. · Blood · 2013 · 671 citations · Full text

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski et al. · The Lancet Haematology · 2016 · 582 citations · Full text

Evidence for an Association Between Chlamydia psittaci and Ocular Adnexal Lymphomas

Andrés J.M. Ferreri, Massimo Guidoboni, Maurilio Ponzoni et al. · JNCI Journal of the National Cancer Institute · 2004 · 552 citations · Full text